Your browser doesn't support javascript.
COVID-19 and emerging viral infections: The case for interferon lambda.
Prokunina-Olsson, Ludmila; Alphonse, Noémie; Dickenson, Ruth E; Durbin, Joan E; Glenn, Jeffrey S; Hartmann, Rune; Kotenko, Sergei V; Lazear, Helen M; O'Brien, Thomas R; Odendall, Charlotte; Onabajo, Olusegun O; Piontkivska, Helen; Santer, Deanna M; Reich, Nancy C; Wack, Andreas; Zanoni, Ivan.
  • Prokunina-Olsson L; Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
  • Alphonse N; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Dickenson RE; Immunoregulation Laboratory, Francis Crick Institute, London, UK.
  • Durbin JE; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Glenn JS; Department of Pathology, Laboratory Medicine and Immunology, Newark, NJ.
  • Hartmann R; Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ.
  • Kotenko SV; Departments of Medicine and Microbiology & Immunology, Stanford University School of Medicine, and Palo Alto Veterans Administration, Palo Alto, CA.
  • Lazear HM; Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
  • O'Brien TR; Center for Immunity and Inflammation, Rutgers New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ.
  • Odendall C; Department of Microbiology, Biochemistry and Molecular Genetics, Rutgers New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ.
  • Onabajo OO; Center for Cell Signaling, Rutgers New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, NJ.
  • Piontkivska H; Department of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Santer DM; Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
  • Reich NC; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Wack A; Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD.
  • Zanoni I; Department of Biological Sciences, School of Biomedical Sciences, Kent State University, Kent, PA.
J Exp Med ; 217(5)2020 05 04.
Article in English | MEDLINE | ID: covidwho-60343
ABSTRACT
With the first reports on coronavirus disease 2019 (COVID-19), which is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the scientific community working in the field of type III IFNs (IFN-λ) realized that this class of IFNs could play an important role in this and other emerging viral infections. In this Viewpoint, we present our opinion on the benefits and potential limitations of using IFN-λ to prevent, limit, and treat these dangerous viral infections.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Interferons / Coronavirus Infections / Betacoronavirus Limits: Humans Language: English Year: 2020 Document Type: Article Affiliation country: Jem.20200653

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Interferons / Coronavirus Infections / Betacoronavirus Limits: Humans Language: English Year: 2020 Document Type: Article Affiliation country: Jem.20200653